The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis. It integrates a variety of BLB’s experimental approaches, including the unique ExoLiver® platform, animal models of cirrhosis, and cellular secretome analysis, among others.
View full article
Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.